literature

SARS_CoV_2 mutation literature information.

Emerging Vaccine-Breakthrough SARS-CoV-2 Variants.

PMID: 35133792 2022 ACS infectious diseases

Result: Second, among the top 25 most observed RBD mutations, T478K, L452Q, N440K, L452R, N501Y, N501T, F490S, A475V, and P384L are the 8 most infectious ones judged by their ability to strengthen the binding with ACE2, as shown in Figure 1c.

Table: A475V

E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody.

PMID: 34915409 2022 International immunopharmacology

Table: A475V

A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients.

PMID: 34896524 2022 Gene

Introduction: While most of alterations in the receptor binding domain (RBD) reduce infectivity, A475V, L452R, V483A, and F490L variants induce resistance to some neutralizing antibodies.

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.

PMID: 34539645 2021 Frontiers in immunology

Abstract: Compared with XG81, XG83 exhibited a higher RBD binding affinity and neutralization potency against wild-typed pseudovirus, variant pseudoviruses with mutated spike proteins, such as D614G, E484Q, and A475V, as well as the authentic SARS-CoV-2 virus.

Introduction: A475V variant at RBD has also been reported to become resistant to some nAbs.

Introduction: Moreover, the recombined antibodies (rAbs) with heavy and light chains from different nAbs produced some new antibodies with a higher neutralization p

Ongoing global and regional adaptive evolution of SARS-CoV-2.

PMID: 34292871 2021 Proc Natl Acad Sci U S A

Result: N234Q, A475V, and V483A were never or rarely found in our alignment, but L452R is a signature of variant B.1.429.

Result: Four more substitutions in the RBD, among others, N234Q, L452R, A475V, and V483A, have been demonstrated to confer antibody resistance.

Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.

PMID: 34307771 2021 Virusdisease

Table: A475V

SARS-CoV-2 receptor-binding mutations and antibody contact sites.

PMID: 34386694 2021 Antibody therapeutics

Introduction: Finally, it has been reported that the antibody neutralization sensitivity of some RBD mutants including A475V, F490L, and V483A (among others) is reduced, suggesting that SARS-CoV-2 is mutating to evade neutralization/RBD binding.

Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.

PMID: 34419160 2021 Infectious diseases of poverty

Table: A475V

Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein.

PMID: 34463219 2021 Journal of biomolecular structure & dynamics

Introduction: The top-binding ligands were additionally screened against biologically significant SARS-CoV-2 mutations occurring in the RBD of the S protein such as N501Y, E484K,

Method: Using the same PDB ID, the SARS-CoV-2 variants (N501Y, E484K, K417N/T, A475V, L452R, V483A, F490L, S477N, N439K) were constructed using UCSF chimera platform by editing necessary amino acids of the S protein via the swapaa command which utilizes information from a rotamer library (Shapovalov & Dunbrack,).

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.

PMID: 34649620 2021 Genome medicine

Result: We demonstrated that some mutations, namely, K417A, F456A, N460A, A475V, F486A, and N487A, led to less binding for multiple group 1 antibodies.

Browser Board

Co-occurred Entities

Filtrator